Olaparib in hormone receptor-positive, HER2-negative metastatic breast cancer with a somatic BRCA2 mutation

Lignende værker

• Olaparib in the metastatic HER2-negative breast cancer setting
  af: L. G. Zhukova, et al.
  Udgivet: (2020-12-01)
• Olaparib and somatic BRCA mutations
  af: George, Angela, et al.
  Udgivet: (2017)
• Hormone Receptor–Positive, HER2-Negative Breast Cancer: Recent Advances and Best Practices
  af: Schwartzberg, Lee, et al.
  Udgivet: (2020)
• Hormone receptor–positive, HER2-negative metastatic breast cancer: redrawing the lines
  af: Matutino, A., et al.
  Udgivet: (2018)
• Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis
  af: Im, Seock-Ah, et al.
  Udgivet: (2020)